Aerovate Therapeutics (NASDAQ:AVTE) Stock Price Up 9.3% - What's Next?

Key Points

• Aerovate shares jumped 9.3% intraday to a high of $25.05 and last traded at $24.40, on a volume spike of about 595,389 shares (roughly a 1,011% increase vs. average), indicating unusually strong trading interest.
• The stock trades well above its technicals (50‑day SMA $16.77, 200‑day SMA $14.41) with a market cap of ~$707.2M and a negative P/E, while the company is a clinical‑stage biopharma developing inhaled anti‑fibrotic/anti‑inflammatory therapies, with a lead candidate in early IPF trials.
• Institutional investors have increased exposure—Goldman Sachs raised its stake to 352,669 shares (~$885k) and funds such as AQR, Rhumbline and Jane Street also added positions, suggesting growing institutional interest.

Aerovate Therapeutics, Inc. (NASDAQ:AVTE - Get Free Report)'s share price rose 9.3% during trading on Friday . The stock traded as high as $25.05 and last traded at $24.40. Approximately 595,389 shares changed hands during mid-day trading, an increase of 1,011% from the average daily volume of 53,591 shares. The stock had previously closed at $22.32.

Aerovate Therapeutics Stock Up 9.3%

The firm's 50-day simple moving average is $16.77 and its 200 day simple moving average is $14.41. The stock has a market capitalization of $707.23 million, a P/E ratio of -8.16 and a beta of 0.95.

Institutional Investors Weigh In On Aerovate Therapeutics

Hedge funds and other institutional investors have recently bought and sold shares of the business. Jane Street Group LLC bought a new stake in Aerovate Therapeutics in the first quarter worth about $28,000. AQR Capital Management LLC raised its position in Aerovate Therapeutics by 14.7% in the first quarter. AQR Capital Management LLC now owns 21,633 shares of the company's stock worth $54,000 after acquiring an additional 2,779 shares in the last quarter. Rhumbline Advisers raised its position in Aerovate Therapeutics by 67.3% in the first quarter. Rhumbline Advisers now owns 22,750 shares of the company's stock worth $57,000 after acquiring an additional 9,154 shares in the last quarter. Finally, Goldman Sachs Group Inc. raised its position in Aerovate Therapeutics by 12.2% in the first quarter. Goldman Sachs Group Inc. now owns 352,669 shares of the company's stock worth $885,000 after acquiring an additional 38,300 shares in the last quarter.

About Aerovate Therapeutics

Aerovate Therapeutics is a clinical-stage biopharmaceutical company focused on developing inhaled therapies for patients with debilitating pulmonary diseases. By leveraging a proprietary aerosol delivery platform, the company aims to deliver potent small-molecule anti-fibrotic and anti-inflammatory agents directly to the lungs, thereby maximizing local drug exposure while minimizing systemic side effects.

The company's lead product candidate is an inhaled formulation of an established anti-fibrotic agent currently in early-phase clinical trials for the treatment of idiopathic pulmonary fibrosis (IPF).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.